Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to ...

While SSRI antidepressants can help in offering relief from symptoms, in comparison, psilocybin or magic mushrooms might be ...

Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) ...

Researchers found that psilocybin therapy provides long-term relief from depressive symptoms similar to escitalopram while ...

Neuronetics announces that TMS coverage has been updated to reduce access barriers for patients with MDD. In line with this, ...

A recent research highlights the potential of psilocybin as a groundbreaking treatment for moderate to severe major ...

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients1 TD is an ...

Here’s a look at the best and worst states in each of the four data categories: mental health provider ratio, suicide rate ...

Fintel reports that on September 23, 2024, EF Hutton initiated coverage of Reviva Pharmaceuticals Holdings (NasdaqCM:RVPH) ...

the active compound in 'magic mushrooms,' may offer more effective outcomes for treating moderate to severe major depressive disorder compared to the commonly prescribed antidepressant escitalopram, a ...

Teva Pharma announces long term efficacy and safety of deutetrabenazine in European patients with debilitating movement disorder tardive dyskinesia: Tel Aviv, Israel Tuesday, Sept ...

SSRI (Selective Serotonin Reuptake Inhibitors) antidepressants like escitalopram improve mood and cognitive functions by ...